Bionutrics snares Kirk for $12M

Generic drug developer Bionutrics is buying Kirk Pharmaceuticals for $12 million in cash and debt. Ronald H. Lane, PhD, Bionutrics' chairman and CEO, said, "This acquisition is an important step in the commercialization of Bionutrics' drug technology and further execution of our business plan. Kirk has relationships with some of the world's largest drug retailers and generic pharmaceutical companies and a growing manufacturing presence in the industry."

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.